Komori
KYORIN Pharmaceutical (4569) · InitiativeFirst statedLatest M&A and Subsidiary Changes (2026-09-30): "Advanced"

Focusing on the New Drug Business by Transferring the Generic Pharmaceutical Business Excluding AGs

First written in FY2026. 2 of 6 entries say "Restated". Latest entry: 2026-09-30.

6entries
1years
5from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst stated2026-04-24 – FY20262026: 62026
Same theme, other companies
Concentration on the innovative pharmaceuticals business through the transfer of the generic pharmaceuticals business and plantsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  2. FY2026First statedAnnual report

    「The Group has considered measures to achieve both sustainable growth through concentrating management resources on the new drug business and contributing to the stable supply of generic pharmaceuticals in Japan. We have now concluded that the best course is to transfer the Group’s generic pharmaceutical business to the Pharmaceutical Co-Creation Organization (provisional name).」

    A basic agreement was signed on 24 April 2026 to transfer the generic pharmaceutical business, excluding the authorized generic business, together with the Takaoka and Inami plants to the Pharmaceutical Co-Creation Organization (provisional name). The definitive agreement is scheduled for the end of September 2026, with the transfer scheduled for 1 April 2027.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet. It last moved in the M&A and Subsidiary Changes of 2026-09-30: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.